Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disorder in which the immune system is unable to mount an adequate immune response.
No HPO annotations are available for this condition.
Age of onset: childhood.
Incontinentia pigmenti (IP) is a disorder of the skin and its appendages, eye, and central nervous system (CNS) that occurs primarily in females and on occasion in males. The largest cohort of individuals with IP in whom the clinical and molecular diagnosis has been confirmed is reported in . Skin. See , , , and . IP manifests in stages that evolve sequentially. The onset and duration of each stage vary among individuals, and not all individuals experience all four stages. The skin abnormalities that define each stage occur along lines of embryonic and fetal skin development known as Blaschko lines . Blaschko lines correspond with cell migration or growth pathways that are established during embryogenesis. Like dermatomes, they are linear on the limbs and circumferential on the trunk.
Source: GeneReviews — "Incontinentia Pigmenti"
Incontinentia pigmenti (IP) should be suspected in individuals with characteristic clinical findings of the skin, teeth, hair, nails, eyes, and CNS, and family history as detailed below.
Major criteria (skin lesions that occur in stages from infancy to adulthood)
Source: GeneReviews — "Incontinentia Pigmenti"
A diagnosis other than incontinentia pigmenti (IP) should be considered when an individual has skeletal involvement (other than secondary to neurologic deficit), gross neurologic deficit, severe alopecia, atypical hyperpigmentation, or gross hypopigmentation. Body segment asymmetry is not usually associated with IP; however, one individual with IP and transverse terminal upper acromelia has been reported . The differential diagnosis for the skin manifestations of IP varies by stage. Because a child with IP may have an infectious comorbidity, findings consistent with an infectious disease should be evaluated accordingly, regardless of the presence of IP.
Source: GeneReviews — "Incontinentia Pigmenti"
Biomarker and diagnostic research for inborn error of immunity has been reported in the published literature.
No approved treatments are currently available for inborn error of immunity. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for inborn error of immunity, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for inborn error of immunity. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Aldesleukin | Aldesleukin | Iovance Biotherapeutics, Inc. | 1989 | — | Designated |
To establish the extent of disease and needs in an individual diagnosed with incontinentia pigmenti (IP), the following evaluations are recommended if they have not already been completed:
Physical examination with particular emphasis on the skin, hair, nails, and neurologic system to establish the presence and extent of manifestations
Consultation with a clinical geneticist and/or genetic counselor
Involvement of a pediatric dermatologist for management of individuals with significant skin involvement
Prompt examination by an ophthalmologist familiar with IP and/or diseases of the retina for evidence of retinal neovascularization
Brain MRI examination and referral to a neurologist for an EEG if seizures, other neurologic abnormalities, or retinal hypervascularization are present
Magnetic resonance angiography, potentially useful in identifying cerebrovascular lesions if the neurologic deficit is consistent with a stroke-like pattern
Developmental evaluation if significant delays are identified
Involvement of a pediatric cardiologist for management of neonates with pulmonary hypertension
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Incontinentia Pigmenti"
1 trial found
No schedule for eye examinations has been established, but the following has been suggested:
Monthly until age three to four months
Every three months between ages four months and one year
Every six months between ages one and three years
Annually after age three years
Neurologic function should be assessed at routine visits with a pediatrician, pediatric neurologist, or developmental pediatrician. Ongoing evaluation by a pedodontist or dentist is appropriate.
Source: GeneReviews — "Incontinentia Pigmenti"
Estimated prevalence: 1-9 in 100,000 (Uncommon).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
356 publications have been identified in PubMed for inborn error of immunity. Kisho has analyzed 244 by research type. Research spans Review / Meta-Analysis (30%), Case Report / Case Series (23%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 74 | 30% |
Patient case studies | 56 | 23% |
Laboratory research | 42 | 17% |
Disease patterns and progression | 29 | 12% |
New treatment approaches | 12 | 5% |
Other research | 11 | 5% |
Testing and diagnosis research | 11 | 5% |
Clinical study results | 9 | 4% |
Luo J (2026). [PMID: 41878438](https://pubmed.ncbi.nlm.nih.gov/41878438/). *Front Immunol*. [Basic Science / Preclinical]
Darbinian E (2026). [PMID: 41326329](https://pubmed.ncbi.nlm.nih.gov/41326329/). *Blood*. [Basic Science / Preclinical]
Duran T (2026). [PMID: 41762386](https://pubmed.ncbi.nlm.nih.gov/41762386/). *Immunol Res*. [Gene Therapy / Novel Therapeutics]
Miedema J (2026). [PMID: 41651390](https://pubmed.ncbi.nlm.nih.gov/41651390/). *Autoimmun Rev*. [Review / Meta-Analysis]
Pan Y (2026). [PMID: 41850246](https://pubmed.ncbi.nlm.nih.gov/41850246/). *Cell Rep Med*. [Basic Science / Preclinical]
Hassan C (2026). [PMID: 41608120](https://pubmed.ncbi.nlm.nih.gov/41608120/). *J Hum Immun*. [Basic Science / Preclinical]
Consolini R (2026). [PMID: 42123030](https://pubmed.ncbi.nlm.nih.gov/42123030/). *J Clin Med*. [Review / Meta-Analysis]
Mao SQ (2026). [PMID: 42135232](https://pubmed.ncbi.nlm.nih.gov/42135232/). *Zhonghua Er Ke Za Zhi*. [Review / Meta-Analysis]
da Rosa LM (2026). [PMID: 41651679](https://pubmed.ncbi.nlm.nih.gov/41651679/). *J Gene Med*. [Basic Science / Preclinical]
Hlongwa L (2026). [PMID: 41692833](https://pubmed.ncbi.nlm.nih.gov/41692833/). *Sci Rep*. [Epidemiology / Natural History]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 1:40 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "Incontinentia Pigmenti"
AI-curated news mentioning inborn error of immunity
Updated Sep 1, 2026
A new publication discusses the recognition and pretransplant management of inborn errors of immunity in the context of hematopoietic cell transplantation. This research highlights critical considerations for improving patient outcomes in these rare conditions.
A new study explores eczema phenotype clustering in patients with inborn errors of immunity and atopy, aiming to enhance understanding of these conditions. This research could inform future therapeutic strategies and patient management.
Recent research highlights advancements in understanding inborn errors of immunity in China, focusing on novel discoveries and treatment paradigms. This study contributes to the growing body of knowledge in immunology and rare diseases.
Recent advancements in gene therapy show promise for treating rare diseases such as inborn errors of immunity, metabolism disorders, haemoglobinopathies, and inherited blindness. However, despite successful clinical results, access to these therapies remains limited.